Heartland Bridge Capital Announces Potential Investment

MAHWAH, N.J., July 25, 2011 /PRNewswire/ -- Heartland Bridge Capital (OTCBB:HLBC) announced that it has signed a term sheet to make an investment in HepatoChem Inc.  HepatoChem, headquartered in Cambridge, MA, offers pharmaceutical and biotech companies reliable and efficient access to small molecule metabolites.  HepatoChem's innovative technology uses biomimetic catalysts to mimic the metabolic function of the liver.  This unique technology, developed in collaboration with Professor John Groves at Princeton University, enables the production of metabolites faster and with greater cost-effectiveness than any other available technology.

"We are very excited at the opportunity to participate in, and support, the commercial development of HepatoChem's extraordinarily innovative technology.  As part of our overall medical technology strategic portfolio, HepatoChem represents an important technology in its ability to advance the drug commercialization process," said James F. Groelinger, HLBC's CEO.  "We're delighted to be developing this relationship with HepatoChem and believe it represents only the first in a series of investments arising from our support of HepatoChem."

Marc Bazin, HepatoChem's founder and CEO, said: "We have found working with Heartland to be complementary in terms of style, financial savvy, and knowledge of the business commercialization process.  I expect HepatoChem's biomimetic technology to be only the first in a line of very important pharmaceutical developments and am delighted to be able to look to Heartland as an ongoing partner."  

About Heartland Bridge Capital, Inc.: Heartland Bridge Capital, Inc. (OTCBB:HLBC) is a public company that, in addition to managing its own operating entities, participates in emerging companies run by exceptionally talented entrepreneurs and operating executives who are dedicated to creating positive change in our world.  HLBC will function as an owner, product developer, and investor focused primarily on providing equity, acquisition debt, or bridge financing to emerging high-growth companies and entrepreneurs in the areas of clean energy, waste management, life sciences, and digital document services.  See www.heartlandbridgecapital.com.  

About HepatoChem Inc.: HepatoChem is a chemistry based technology platform company with a primary focus on metabolite production from bioactive small molecules.  Founded by Marc Bazin, previously with Pfizer, Inc., and Prof. John T. Groves, the Hugh Stott Taylor Chair of Chemistry at Princeton University, HepatoChem is dedicated to developing technologies that help pharmaceutical company improve the quality of drug development pipelines.  HepatoChem offers a unique and powerful solution to resolve the lack of rapid and efficient metabolite access in drug discovery.  See www.hepatochem.com.

Safe Harbor Notice

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995).  Heartland Bridge Capital, Inc. cautions that statements made in this news release relating to the potential investment in HepatoChem Inc. and the business direction of the Company constitute forward-looking statements and makes no guarantee of future performance.  Forward-looking statements are based on estimates and opinions of management at the time statements are made.  These statements may address issues that involve significant risks, uncertainties, estimates, and assumptions made by management.  Actual results could differ materially from current projections or implied results.  Heartland Bridge Capital, Inc. undertakes no obligation to revise these statements following the date of this news release.

For more information or to schedule an interview with James F. Groelinger, please contact him at (201) 512-8732 or email [email protected].

Contact:     James F. Groelinger, Chairman, President, and CEO
                  (phone): 1-201-512-8732; (e-mail): [email protected]

SOURCE Heartland Bridge Capital, Inc.